Generate Biomedicines, Inc. (GENB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$14.27

From 52W high−30.52%

Volume635754.00

Market cap$1.82B

P/E (TTM)—

P/S (TTM)57.0x

Div yield—

Key dataNov 4, 2026

Open

$14.27

From 52W high

−30.52%

Volume

635754.00

Market cap

$1.82B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.8x

P/E (TTM)

—

RSI (14)

48.6

MomentumView details →

1D Return

+2.24%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.8x

EV/Sales

44.6x

P/S (TTM)

57.0x

P/B (TTM)

4.0x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−636.99%

EBITDA Margin

−653.71%

ROE (TTM)

−44.55%

ROA (TTM)

−36.17%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+55.89%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+2.24%

YTD Return

—

1Y Return

—

RSI (14)

48.6

vs 50D SMA

−7.11%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

8.30x

Quick Ratio

8.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−2.30%

Beats (12Q)

0/12

Next Q EPS Est

−$0.58

Avg Surprise (4Q)

−70.04%

Rev Surprise

19.13%

Financials snapshotView financials →

Revenue (TTM)

32.49M

Net Income (TTM)

−222.81M

Op. CF (TTM)

−240.26M

Next earningsNov 5, 2026 →

Latest newsMore news →

Generate Biomedicines, Inc. and Zealand Pharma A/S entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.22d ago

Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of the AI-engineered CAR T therapy GB-5267 for ovarian cancer, with the first patient treated.34d ago

Similar companies

Tri-Continental CorporationTY Spring Valley Acquisition Corp. IIISVACU American Century Inflation Adjs Bond InvACITX Trinity Capital Inc. 7.875% Notes Due 2029TRINI China Vered Financial Holding Corporation Limited00245.HK DFA Intl Hi Relatv Profitability InstlDIHRX Find similar companies →

Latest newsMore news →

Generate Biomedicines, Inc. and Zealand Pharma A/S entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.22d ago Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of the AI-engineered CAR T therapy GB-5267 for ovarian cancer, with the first patient treated.34d ago